- Home
- ONMD vs IRD Comparison
ONMD vs IRD Comparison
Compare ONMD & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONMD
- IRD
- Stock Information
- Founded
- ONMD 2006
- IRD 2018
- Country
- ONMD United States
- IRD United States
- Employees
- ONMD N/A
- IRD N/A
- Industry
- ONMD
- IRD
- Sector
- ONMD
- IRD
- Exchange
- ONMD Nasdaq
- IRD NYSE
- Market Cap
- ONMD 32.5M
- IRD 35.7M
- IPO Year
- ONMD N/A
- IRD N/A
- Fundamental
- Price
- ONMD $0.99
- IRD $1.10
- Analyst Decision
- ONMD
- IRD Strong Buy
- Analyst Count
- ONMD 0
- IRD 1
- Target Price
- ONMD N/A
- IRD $8.00
- AVG Volume (30 Days)
- ONMD 90.9K
- IRD 169.0K
- Earning Date
- ONMD 12-17-2024
- IRD 03-04-2025
- Dividend Yield
- ONMD N/A
- IRD N/A
- EPS Growth
- ONMD N/A
- IRD N/A
- EPS
- ONMD 0.01
- IRD N/A
- Revenue
- ONMD $957,651.00
- IRD $8,381,000.00
- Revenue This Year
- ONMD N/A
- IRD N/A
- Revenue Next Year
- ONMD N/A
- IRD $29.37
- P/E Ratio
- ONMD $120.13
- IRD N/A
- Revenue Growth
- ONMD 1.36
- IRD N/A
- 52 Week Low
- ONMD $0.46
- IRD $0.81
- 52 Week High
- ONMD $3.37
- IRD $2.65
- Technical
- Relative Strength Index (RSI)
- ONMD 45.51
- IRD N/A
- Support Level
- ONMD $0.90
- IRD N/A
- Resistance Level
- ONMD $1.06
- IRD N/A
- Average True Range (ATR)
- ONMD 0.07
- IRD 0.00
- MACD
- ONMD 0.00
- IRD 0.00
- Stochastic Oscillator
- ONMD 60.00
- IRD 0.00
About ONMD OneMedNet Corp
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real-World Data or iRWDTM. OneMedNet's innovative solutions connect healthcare providers and patients satisfying a crucial need within the Life Sciences field offering direct access to clinical images and the associated contextual patient record.
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.